Wednesday, October 11, 2023
FEops, a leader in personalized predictive planning for structural heart interventions, has announced a partnership with TeraRecon, a part of ConcertAI, to expand the commercialization of FEops HEARTguide for Left Atrial Appendage (LAA) occlusion workflows, with a primary focus on the US market.
Matthieu De Beule, CEO of FEops, expressed excitement about the collaboration, stating, "We are thrilled to join forces with TeraRecon and integrate our FEops HEARTguide™ solution into TeraRecon's software. This partnership underscores our shared vision of utilizing technology to revolutionize healthcare. By incorporating FEops HEARTguide's advanced capabilities into TeraRecon's robust platform, we aim to equip clinicians with a tool that empowers them to provide optimized care to patients with cardiovascular conditions."
FEops HEARTguide™ is a one-of-a-kind cloud-based procedure planning solution in the field of structural heart interventions, based on digital twin technology. With the introduction of the LAA occlusion workflow in the US, FEops HEARTguide™ allows American physicians to virtually model clinical scenarios involving different implant positions and sizes of FDA-cleared LAA devices, aiding physicians in the selection of the optimal size and position for every individual patient before the intervention. Established clinical evidence from the PREDICT-LAA trial has shown that FEops' digital twin-based planning for LAA closure results in improved procedure efficiency and outcomes as compared to standard CT-based planning.
Dan McSweeney, President of TeraRecon, highlighted the significance of the addition of FEops HEARTguide™ to their comprehensive offerings, particularly in cardiology and cardiovascular care. " Through the integration of FEops' advanced digital twin AI solution into TeraRecon's platform, we are well-positioned to offer clinicians a distinctive tool that enhances the efficiency of pre-treatment Simplifying the planning of structural heart interventions through CT-based methods, ultimately enabling clinicians to make more informed decisions.
The collaboration between FEops and TeraRecon represents a significant step toward personalized and data-driven cardiac care. The integration of TeraRecon's solutions and FEops' HEARTguide™ solution exemplifies the potential of AI to reshape the future of medical diagnosis and treatment planning.
Source:businesswire.com
